US20080020060A1 - Process for treating rhinitis - Google Patents

Process for treating rhinitis Download PDF

Info

Publication number
US20080020060A1
US20080020060A1 US11/768,261 US76826107A US2008020060A1 US 20080020060 A1 US20080020060 A1 US 20080020060A1 US 76826107 A US76826107 A US 76826107A US 2008020060 A1 US2008020060 A1 US 2008020060A1
Authority
US
United States
Prior art keywords
rhinitis
silver
colloidal suspension
alloys
providing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/768,261
Inventor
Robert R. Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/768,261 priority Critical patent/US20080020060A1/en
Publication of US20080020060A1 publication Critical patent/US20080020060A1/en
Priority to CA 2635464 priority patent/CA2635464A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Definitions

  • This invention relates generally to the treatment and control of rhinitis, and more particularly to the use of silver and silver alloys in the treatment and control of rhinitis.
  • Rhinitis has adversely affected humankind literally for centuries, and even more so since the advent of the industrial age. More recently the existence of a multitude of airborne allergens, pathogens, and irritants has resulted in substantial portions of the populations of all industrialized nations being afflicted to a greater or lesser degree with rhinitis.
  • elemental silver and/or alloys of silver are employed in the treatment and control of rhinitis. More specifically, a colloidal suspension comprising de-ionized water and nanoparticles of silver and/or one more alloys of silver is utilized in the treatment of rhinitis.
  • a colloidal suspension of elemental silver and/or one or more alloys of silver is mixed with a selected over-the-counter rhinitis treatment medicine.
  • the resulting mixture is discharged into the nostrils of a patient in the form of a spray. In most instances a once daily administration of the mixture is sufficient to completely control rhinitis.
  • a colloidal suspension of elemental silver and/or one or more silver alloys is mixed with a selected prescription rhinitis treatment medicine.
  • the resulting mixture is discharged into the nostrils of a patient in the form of a spray. In most instances a once daily administration of the mixture is sufficient to completely control rhinitis.
  • a colloidal suspension comprising nanoparticles of elemental silver is provided.
  • the colloidal suspension comprises de-ionized water and 99.99% pure silver.
  • the colloidal suspension comprises approximately 20 ppm silver.
  • the foregoing colloidal suspension comprising substantially pure silver is mixed with an over-the-counter rhinitis remedy.
  • over-the-counter rhinitis medicines which may be used in the practice of the invention include AFRIN® (oxymetazoline HCl), NEO-SYNEPHRINE® (phenylephrine HCl 1.0%); and DRISTAN® (oxymetazoline HCl 0.05%).
  • the colloidal suspension of substantially pure elemental silver and the selected over-the-counter rhinitis medicine are mixed at a ratio of 1:1.
  • the resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
  • a colloidal suspension comprising nanoparticles of elemental silver is provided.
  • the colloidal suspension comprises de-ionized water and 99.99% pure silver.
  • the colloidal suspension comprises approximately 20 ppm silver.
  • the foregoing colloidal suspension comprising substantially pure silver is mixed with a prescription rhinitis remedy.
  • prescription rhinitis medicines which may be used in the practice of the invention include FLONASE® (fluticasone propionate) NASONEX® (mometasone furoate monohydrate), NASACORT® (triamcinolone acetonide, and BECONTAS AQ® (beclomethasone dipropionate, monohydrate).
  • the colloidal suspension of substantially pure elemental silver and the selected prescription rhinitis medicine are mixed at ratio of 1:1.
  • the resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
  • a colloidal suspension comprising nanoparticles of one or more alloys of silver is provided.
  • the colloidal suspension comprises de-ionized water and one or more substantially pure silver alloys.
  • the colloidal suspension may comprise approximately 20 ppm of one or more silver alloys.
  • the elements that may be alloyed with silver for use in the practice of the invention include the following: Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
  • colloidal suspension comprising substantially one or more alloys of silver is mixed with an over-the-counter rhinitis remedy.
  • over-the-counter rhinitis medicines which may be used in the practice of the invention include AFRIN® (oxymetazoline HCl), NEO-SYNEPHRINE® (phenylephrine HCl 1.0%), and DRISTAN® (oxymetazoline HCl 0.05).
  • the colloidal suspension of one or more alloys of silver and the selected over-the-counter rhinitis medicine are mixed at a ratio of 1:1.
  • the resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
  • a colloidal suspension comprising nanoparticles of one or more alloys of silver is provided.
  • the colloidal suspension comprises de-ionized water and one or more substantially pure silver alloys.
  • the colloidal suspension may comprise approximately 20 ppm of one or more silver alloys.
  • the elements that may be alloyed with silver for use in the practice of the invention include the following: Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
  • the foregoing colloidal suspension comprising substantially pure silver is mixed with a prescription rhinitis remedy.
  • prescription rhinitis medicines which may be used in the practice of the invention include FLONASE® (fluticasone propionate); NASONEX® (mometasone furoate monohydrate), NASACORT® (triamcinolone acetonide), and BECONAS AQ® (beclomethasone dipropionate, monohydrate).
  • the colloidal suspension of substantially pure elemental silver and the selected prescription rhinitis medicine are mixed at a ratio of 1:1.
  • the resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.

Abstract

A colloidal suspension comprising elemental silver and/or one or more alloys of silver is mixed with either an over-the-counter rhinitis medicine or a prescription rhinitis medicine. The resulting mixture is administered to rhinitis patients in the form of a spray.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • Applicant claims priority based on provisional patent application Ser. No. 60/820,003 filed Jul. 21, 2006, the entire content of which is incorporated herein by reference.
    • TECHNICAL FIELD
  • This invention relates generally to the treatment and control of rhinitis, and more particularly to the use of silver and silver alloys in the treatment and control of rhinitis.
    • BACKGROUND AND SUMMARY OF THE INVENTION
  • Rhinitis has adversely affected humankind literally for centuries, and even more so since the advent of the industrial age. More recently the existence of a multitude of airborne allergens, pathogens, and irritants has resulted in substantial portions of the populations of all industrialized nations being afflicted to a greater or lesser degree with rhinitis.
  • Over the centuries a wide variety of homeopathic remedies, patent medicines, over-the-counter drugs, and prescription drugs have been available for the treatment of rhinitis. Despite the almost universal availability of existing rhinitis treatments, widespread control of rhinitis symptoms has not yet been achieved. Thus, a need exists for a method of treating rhinitis which is both effective and readily available.
  • The anti-microbial benefits of silver have long been recognized. For example, from ancient times through the present people have recognized the fact that foods and beverages are less likely to spoil when stored, prepared, and served in silver cooking utensils, serving utensils, and beverage containers.
  • In accordance with the present invention elemental silver and/or alloys of silver are employed in the treatment and control of rhinitis. More specifically, a colloidal suspension comprising de-ionized water and nanoparticles of silver and/or one more alloys of silver is utilized in the treatment of rhinitis.
  • In accordance with a first embodiment of the invention a colloidal suspension of elemental silver and/or one or more alloys of silver is mixed with a selected over-the-counter rhinitis treatment medicine. The resulting mixture is discharged into the nostrils of a patient in the form of a spray. In most instances a once daily administration of the mixture is sufficient to completely control rhinitis.
  • In accordance with a second embodiment of the invention a colloidal suspension of elemental silver and/or one or more silver alloys is mixed with a selected prescription rhinitis treatment medicine. The resulting mixture is discharged into the nostrils of a patient in the form of a spray. In most instances a once daily administration of the mixture is sufficient to completely control rhinitis.
    • DETAILED DESCRIPTION EXAMPLE 1
  • A colloidal suspension comprising nanoparticles of elemental silver is provided. The colloidal suspension comprises de-ionized water and 99.99% pure silver. The colloidal suspension comprises approximately 20 ppm silver.
  • The foregoing colloidal suspension comprising substantially pure silver is mixed with an over-the-counter rhinitis remedy. Examples of over-the-counter rhinitis medicines which may be used in the practice of the invention include AFRIN® (oxymetazoline HCl), NEO-SYNEPHRINE® (phenylephrine HCl 1.0%); and DRISTAN® (oxymetazoline HCl 0.05%).
  • The colloidal suspension of substantially pure elemental silver and the selected over-the-counter rhinitis medicine are mixed at a ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
    • EXAMPLE 2
  • A colloidal suspension comprising nanoparticles of elemental silver is provided. The colloidal suspension comprises de-ionized water and 99.99% pure silver. The colloidal suspension comprises approximately 20 ppm silver.
  • The foregoing colloidal suspension comprising substantially pure silver is mixed with a prescription rhinitis remedy. Examples of prescription rhinitis medicines which may be used in the practice of the invention include FLONASE® (fluticasone propionate) NASONEX® (mometasone furoate monohydrate), NASACORT® (triamcinolone acetonide, and BECONTAS AQ® (beclomethasone dipropionate, monohydrate).
  • The colloidal suspension of substantially pure elemental silver and the selected prescription rhinitis medicine are mixed at ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
    • EXAMPLE 3
  • A colloidal suspension comprising nanoparticles of one or more alloys of silver is provided. The colloidal suspension comprises de-ionized water and one or more substantially pure silver alloys. The colloidal suspension may comprise approximately 20 ppm of one or more silver alloys. The elements that may be alloyed with silver for use in the practice of the invention include the following: Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
  • The foregoing colloidal suspension comprising substantially one or more alloys of silver is mixed with an over-the-counter rhinitis remedy. Examples of over-the-counter rhinitis medicines which may be used in the practice of the invention include AFRIN® (oxymetazoline HCl), NEO-SYNEPHRINE® (phenylephrine HCl 1.0%), and DRISTAN® (oxymetazoline HCl 0.05).
  • The colloidal suspension of one or more alloys of silver and the selected over-the-counter rhinitis medicine are mixed at a ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
    • EXAMPLE 4
  • A colloidal suspension comprising nanoparticles of one or more alloys of silver is provided. The colloidal suspension comprises de-ionized water and one or more substantially pure silver alloys. The colloidal suspension may comprise approximately 20 ppm of one or more silver alloys. The elements that may be alloyed with silver for use in the practice of the invention include the following: Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
  • The foregoing colloidal suspension comprising substantially pure silver is mixed with a prescription rhinitis remedy. Examples of prescription rhinitis medicines which may be used in the practice of the invention include FLONASE® (fluticasone propionate); NASONEX® (mometasone furoate monohydrate), NASACORT® (triamcinolone acetonide), and BECONAS AQ® (beclomethasone dipropionate, monohydrate).
  • The colloidal suspension of substantially pure elemental silver and the selected prescription rhinitis medicine are mixed at a ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
  • Although preferred embodiments of the invention have been illustrated in the accompanying Drawings and described in the foregoing Detailed Description, it will be understood that the invention is not limited to the embodiments disclosed, but is capable of numerous rearrangements, modifications, and substitutions of parts and elements without departing from the spirit of the invention.

Claims (12)

1. A method of treating rhinitis comprising the steps of:
providing a colloidal suspension of elemental silver;
providing a predetermined over-the-counter rhinitis treatment medicine;
mixing the colloidal suspension of elemental silver with the over-the-counter rhinitis treatment medicine at a predetermined ratio; and
administering the resulting mixture into the nostrils of a rhinitis patient in the form of a spray.
2. The method of treating rhinitis according to claim 1 wherein the colloidal suspension of elemental silver comprises de-ionized water and 20 ppm of 99.9% pure silver.
3. The method of treating rhinitis according to claim 1 wherein the predetermined ratio is 1:1.
4. A method of treating rhinitis comprising the steps of:
providing a colloidal suspension of elemental silver;
providing a predetermined prescription rhinitis treatment medicine;
mixing the colloidal suspension of elemental silver with the prescription rhinitis treatment medicine at a predetermined ratio; and
administering the resulting mixture into the nostrils of a rhinitis patient in the form of a spray.
5. The method of treating rhinitis according to claim 4 wherein the colloidal suspension of elemental silver comprises de-ionized water and 20 ppm of 99.9% pure silver.
6. The method of treating rhinitis according to claim 4 wherein the predetermined ratio is 1:1.
7. A method of treating rhinitis comprising the steps of:
providing a colloidal suspension of one or more alloys of silver;
providing a predetermined over-the-counter rhinitis treatment medicine,
mixing the colloidal suspension of one or more alloys of silver with the over-the-counter rhinitis treatment medicine at a predetermined ratio; and
administering the resulting mixture into the nostrils of a rhinitis patient in the form of a spray.
8. The method of treating rhinitis according to claim 7 wherein at least one of the alloys of silver comprises silver alloyed with an element selected from the group consisting of Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
9. The method of treating rhinitis according to claim 7 wherein the predetermined ratio is 1:1.
10. A method of treating rhinitis comprising the steps of:
providing a colloidal suspension of one or more alloys of silver;
providing a predetermined prescription rhinitis treatment medicine;
mixing the colloidal suspension of one or more alloys of silver with the prescription rhinitis treatment medicine at a predetermined ratio; and
administering the resulting mixture into the nostrils of a rhinitis patient in the form of a spray.
11. The method of treating rhinitis according to claim 10 wherein at least one of the alloys of silver comprises silver alloyed with an element selected from the group consisting of Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
12. The method of treating rhinitis according to claim 10 wherein the predetermined ratio is 1:1.
US11/768,261 2006-07-21 2007-06-26 Process for treating rhinitis Abandoned US20080020060A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/768,261 US20080020060A1 (en) 2006-07-21 2007-06-26 Process for treating rhinitis
CA 2635464 CA2635464A1 (en) 2007-06-26 2008-06-20 Process for treating rhinitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82000306P 2006-07-21 2006-07-21
US11/768,261 US20080020060A1 (en) 2006-07-21 2007-06-26 Process for treating rhinitis

Publications (1)

Publication Number Publication Date
US20080020060A1 true US20080020060A1 (en) 2008-01-24

Family

ID=38971737

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/768,261 Abandoned US20080020060A1 (en) 2006-07-21 2007-06-26 Process for treating rhinitis

Country Status (1)

Country Link
US (1) US20080020060A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20090077A1 (en) * 2009-02-20 2010-08-21 D M G Italia S R L PHARMACEUTICAL COMPOSITION CONTAINING MICROCOLLOIDAL SILVER AND CARBOSSIMETHYLBETHAGLAN FOR DISINFECTION OF NASAL MUCOSA AND ITS PREPARATION PROCEDURE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970240A (en) * 1989-10-18 1990-11-13 Schering Corporation Fruity flavored nasal decongestant composition
US20040110738A1 (en) * 2002-10-22 2004-06-10 Gillis Scott H. Prophylactic treatment methods
US6899903B2 (en) * 2002-06-25 2005-05-31 Patrick Quillin Composition for cleansing the sinuses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970240A (en) * 1989-10-18 1990-11-13 Schering Corporation Fruity flavored nasal decongestant composition
US6899903B2 (en) * 2002-06-25 2005-05-31 Patrick Quillin Composition for cleansing the sinuses
US20040110738A1 (en) * 2002-10-22 2004-06-10 Gillis Scott H. Prophylactic treatment methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20090077A1 (en) * 2009-02-20 2010-08-21 D M G Italia S R L PHARMACEUTICAL COMPOSITION CONTAINING MICROCOLLOIDAL SILVER AND CARBOSSIMETHYLBETHAGLAN FOR DISINFECTION OF NASAL MUCOSA AND ITS PREPARATION PROCEDURE
WO2010095158A1 (en) * 2009-02-20 2010-08-26 D. M. G. Italia Srl Pharmaceutical composition containing microcolloidal silver and carboxymethyl beta glucan for disinfection of the nasal mucosae, and process for preparation thereof

Similar Documents

Publication Publication Date Title
WO2010025236A1 (en) Composition and method for treating colds
TW200808374A (en) Sugar-free storage-stable antihistaminic syrups
US20080020060A1 (en) Process for treating rhinitis
EP2799074A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
Cox et al. Medical treatment of nasal airway obstruction
US20070286812A1 (en) Nasal formulation
US20210100865A1 (en) Composition and methods of use for immune system support
CA2635464A1 (en) Process for treating rhinitis
US20040180868A1 (en) Composition and method for treating inflammations by reducing C-reactive protein
Davis et al. Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection
JP2009073749A5 (en)
US20080254053A1 (en) Protocol for treatment of diabetes
Kroslak Efficacy and acceptability of fusafungine*, a local treatment for both nose and throat infections, in adult patients with upper respiratory tract infections
US20200245646A1 (en) Therapeutic composition including carbonated solution
EP3897579A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
Davis Summer" sniffles": ear, nose and throat
Kendon Due diligence in practice: or, do you know what your patients are taking?
US10179122B2 (en) Use of melatonin
WO2005089171A2 (en) Protocol for improving vision
van Schaik Dexamfetamine: Various toxicities: 4 case reports
Crane Long-acting beta agonists--prescribe with care
Tosca et al. Treatment of Allergic Rhinitis in Clinical Practice
US20040192660A1 (en) Protocol for improving vision
Miller Viaskin Peanut patch increases protection from allergy over time
US20130059918A1 (en) Throat irritation relief beverage

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION